• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Leukemia and Lymphoma

The AJMC® Leukemia & Lymphoma compendium is a comprehensive resource for clinical news and expert insights for the blood cancers and their treatments.

Latest News

FDA Approved - chrisdorney - stock.adobe.com.jpg
Zanubrutinib Plus Obinutuzumab Granted Accelerated FDA Approval for R/R Follicular Lymphoma

March 7th 2024

The FDA granted accelerated approval to combination zanubrutinib and obinutuzumab for the treatment of relapsed or refractory (R/R) follicular lymphoma following 2 or more lines of therapy.

Red Blood Cells - Design Cells stock.adobe.com
alloHSCT Yields Benefits in R/R AML Regardless of Leukemia Burden

December 22nd 2023

Highlights from ASH 2023
ICYMI: Highlights From ASH 2023

December 20th 2023

Zanubrutinib rendering | Image credit: molekuul.be - stock.adobe.com
Zanubrutinib May Be Viable Option After Acalabrutinib Intolerance in B-Cell Malignancies

December 11th 2023

Blood cells flowing | Image credit: Катерина Євтехова - stock.adobe.com
Health Care Resource Use, Cost Burden Appear Substantial in R/R B-Cell ALL

December 8th 2023

Latest CME Events & Activities

CAR T-Cell Therapy Advances in Lymphoma: Implications for Managed Care

1.5 Credits / Hematology, Oncology

View More

Evidence-Based Oncology: Discerning Novel Approaches, Recent Advances, and the Managed Care Considerations for Targeted Treatments in CLL

2.0 Credits / Hematology, Oncology

View More

Leveraging Managed Care to Optimize Patient Outcomes in Acute Myeloid Leukemia

1.5 Credits / Hematology, Oncology

View More

Leveraging Managed Care to Increase Access to BCMA-Directed Treatment and Equitable Care in Multiple Myeloma

1.5 Credits / Hematology, Oncology

View More

New Pathways in Care for Myelofibrosis: Optimizing Treatment to Improve Outcomes

1.5 Credits / Hematology, Oncology

View More

Managed Care Considerations on the Evolving Role of Bispecific Antibodies in Hematologic Malignancies

1.5 Credits / Hematology, Oncology

View More

Continuing the Conversation in Myelofibrosis: The Role of Managed Care in Supporting Treatment Goals Through Appropriate Use of Emerging Therapies

1.0 Credits / Hematology, Oncology

View More

Supporting Safe, Effective, and Equitable Access to B-Cell Maturation Antigen (BCMA)-Directed Treatments in Multiple Myeloma: Strategies for Specialty and Managed Care Pharmac...

1.5 Credit / Hematology, Oncology

View More

Advances in the Treatment of Myelofibrosis: Updates and Considerations for Managed Care Professionals

1.0 Credit / Hematology, Oncology

View More

More News

© 2024 MJH Life Sciences
AJMC®
All rights reserved.